Reference number(s)
2602-H

SPECIALTY QUANTITY LIMIT PROGRAM

OLUMIANT (baricitinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Olumiant 1 mg tablet	30 tablets per 30 days	For moderate renal impairment: Reduce dose to 1 mg once daily.
Olumiant 2 mg tablet	30 tablets per 30 days	2 mg once daily

III. REFERENCE

1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; May 2018.

DOCUMENT HISTORY
Created: Specialty Clinical Development (CN) 06/2018
Revised: JC 06/2019 (annual-no changes), JC 11/2019 (added 1 mg)
Reviewed: CDPR/ EPA 06/2018, JG 06/2019, CHART 11/21/2019
External Review: 06/2018, 09/2018

CVS caremark™